AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6695841
Drug: All meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All meal sizes (15 to 75% of daily energy requirements)
Trial: 20650444
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment plus renal artery stenting
Trial: 10584049
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (50 mg caffeine and 90 mg epigallocatechin gallate)
Trial: 19705245
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg dexamethasone
Trial: 25793707
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg sodium valproate (patients with aura)
Trial: 25793707
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg dexamethasone (patients with aura)
Trial: 17476567
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion during hyperglycaemia
Trial: 15221621
Drug: Proximal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal steroid injections (betamethasone)
Trial: 15221621
Drug: Distal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal steroid injections (betamethasone)
Trial: 8502438
Drug: Narcotic analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcotic analgesic (standard intervention)
Trial: 3545642
Drug: Lipid infusion
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid infusion into the duodenum
Trial: 3545642
Drug: Lipid infusion
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid infusion into the ileum
Trial: 27000249
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon beta‐1a (SC IFNB‐1a) 44 μg three times weekly
Trial: 25783198
Drug: Low-dose multislice
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose multislice computed tomography (MSCT) screening
Trial: 15526804
Drug: salmeterol/fluticasone combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol/fluticasone combination 50/500mcg bid
Trial: 11212999
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (50 microg every 6 h)
Trial: 9043898
Drug: Humegon (FSH/LH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humegon (FSH/LH ratio 1:1) via subcutaneous (s.c.) administration
Trial: 9043898
Drug: Humegon (FSH/LH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humegon (FSH/LH ratio 1:1) via intramuscular (i.m.) administration
Trial: 9043898
Drug: Normegon (FSH/LH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normegon (FSH/LH ratio 3:1) via subcutaneous (s.c.) administration
Trial: 9043898
Drug: Normegon (FSH/LH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normegon (FSH/LH ratio 3:1) via intramuscular (i.m.) administration
Trial: 9043898
Drug: Both preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both preparations (Humegon and Normegon)
Trial: 7779855
Drug: BT563 (murine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT563 (murine anti-interleukin-2 receptor monoclonal antibody)
Trial: 7779855
Drug: Murine monoclonal
RxNorm normalized name: 131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I
DrugBank: Apamistamab iodine I-131 (DB16748)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Murine monoclonal CD3 antibody
Trial: 7779855
Drug: BT563 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BT563 treatment
Trial: 31322086
Drug: Meldonium plus
RxNorm normalized name: meldonium
DrugBank: Meldonium (DB13723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meldonium plus standard antianginal and antiarrhythmic therapy for 2 months
Trial: 31322086
Drug: Standard antianginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antianginal and antiarrhythmic therapy only
Trial: 23122974
Drug: Esmolol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (0.5 mg/kg loading dose followed by 30 μg/kg/min infusion)
Trial: 30260460
Drug: L-arginine 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine 6 g/day
Trial: 27392904
Drug: Intranasal calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal calcitonin for 6 weeks
Trial: 25917265
Drug: Balneotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneotherapy with mud-pack and hot pool treatments
Trial: 21115455
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 600 mg every 12 h for 5-14 days
Trial: 21115454
Drug: Vancomycin 1
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 1 g plus aztreonam 1 g every 12 h for 5-14 days
Trial: 16758259
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg twice daily for 18 days
Trial: 16758259
Drug: Baseline S‐warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline S‐warfarin AUC(0‐infinity)
Trial: 16758259
Drug: Inhibition period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibition period S‐warfarin AUC(0‐infinity)
Trial: 8966087
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (15 ml daily for 12 weeks)
Trial: 7880657
Drug: Single-dose spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose spinal anaesthesia (SDSA) with a 24‐gauge x 103‐mm Sprotte spinal needle
Trial: 7880657
Drug: Single-dose spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose spinal anaesthesia (SDSA)
Trial: 7880657
Drug: Continuous spinal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous spinal anaesthesia (CSA) and Single-dose spinal anaesthesia (SDSA)
Trial: 2906764
Drug: Low-dose combined
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combined oral contraceptive (OC)
Trial: 2148146
Drug: Progestogen-only pill
RxNorm normalized name: vaginal ring with progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestogen-only pill
Trial: 28703949
Drug: Preferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferred treatment assignment
Trial: 26714490
Drug: Bowel-cleansing preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel-cleansing preparations satisfaction measure (Domain 1)
Trial: 22053621
Drug: Hemodialyzed patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodialyzed patients without glucose (HD-g(-))
Trial: 22053621
Drug: Hemodialyzed patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodialyzed patients with glucose (HD-g(+))
Trial: 17111989
Drug: Standard psychiatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard psychiatric treatments (treatment as usual)
Trial: 12583870
Drug: Granisetron (GRA)
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron (GRA) 1 mg/ml injected into the masseter muscle
Trial: 10898121
Drug: Amtolmetin guacyl
RxNorm normalized name: Amtolmetin guacil
DrugBank: Amtolmetin guacil (DB16088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amtolmetin guacyl (600 mg on an empty stomach, once daily for 30 days)
Trial: 10898121
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg on a full stomach, once daily for 30 days)
Trial: 1622733
Drug: PSK (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSK (3.0 g orally before surgery, daily or every other day)
Trial: 26872703
Drug: Web-based coaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based coaching program (fully automated) including education, motivation, exercise guidance, daily text message reminders, and weekly feedback.
Trial: 24155058
Drug: Rifabutin 300
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin 300 mg once daily for 14 days plus etravirine 800 mg twice daily for 21 days (days 8-21)
Trial: 24155058
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg twice daily for 13 days plus etravirine 200 mg twice daily for 8 days (days 6-13)
Trial: 22015542
Drug: SMART treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART treatment (budesonide/formoterol 80/4.5 μg Turbuhaler®, two puffs once daily and extra inhalations as needed)
Trial: 22015542
Drug: SMART treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART treatment
Trial: 22015542
Drug: UC treatment
RxNorm normalized name: Astri-UC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC treatment
Trial: 20439575
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (2 mg/d subcutaneously)
Trial: 20439575
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (2 mg/d)
Trial: 20439575
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (2 mg/d) with testosterone (250 mg/wk intramuscularly)
Trial: 625655
Drug: Diclofenac (Voltaren)
RxNorm normalized name: diclofenac Topical Gel [Voltaren]
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac (Voltaren) 75 mg daily from week 4
Trial: 625655
Drug: Naproxen (Proxen)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen (Proxen) 500 mg daily from week 4
Trial: 24055681
Drug: VEN‐Progressive Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEN‐Progressive Muscle Relaxation therapy (PMR)
Trial: 20739054
Drug: Eltrombopag (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (50 mg once daily)
Trial: 19169289
Drug: Pegfilgrastim 12
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim 12 mg
Trial: 19169289
Drug: Daily filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily filgrastim (10 microg/kg for < or =7 days)
Trial: 19169289
Drug: Daily filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily filgrastim (5 microg/kg/day for < or =14 days)
Trial: 15480402
Drug: Pamidronate infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate infusion
Trial: 11296091
Drug: SR141716 (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR141716 (90 mg)
Trial: 11296091
Drug: SR141716 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR141716 (1, 3, 10, 30, and 90 mg)
Trial: 9416985
Drug: Other active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other active drugs
Trial: 8293730
Drug: Anxiety before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anxiety before the 1st infusion
Trial: 3323290
Drug: iv calcium
RxNorm normalized name: Viactiv Calcium Plus D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv calcium infusion
Trial: 3323290
Drug: oral diltiazem
RxNorm normalized name: diltiazem Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral diltiazem administration for one week
Trial: 3323290
Drug: acute iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acute iv diltiazem infusion
Trial: 3323290
Drug: calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: calcium and diltiazem treatments
Trial: 24144628
Drug: Potato-derived balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potato-derived balanced 6% HES 130/0.42 with 500 mL of Ringer's lactate (HESPRL)
Trial: 24144628
Drug: Waxy maize-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waxy maize-derived balanced 6% HES 130/0.4 with 500 mL of Ringer's lactate (HESMRL)
Trial: 14743119
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia with 12-15 ml of ropivacaine 0.75% and fentanyl 5 microg/ml followed by light general anesthesia and postoperative epidural analgesia with ropivacaine 0.2% and fentanyl 2 mg/ml
Trial: 14743119
Drug: Inhalatory or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalatory or intravenous general anesthesia and intravenous tramadol postoperative analgesia
Trial: 11078493
Drug: 4‐HPR (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐HPR (200 mg/d)
Trial: 27049107
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg sodium hyaluronate plus saline solution
Trial: 22664486
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy with an implantable defibrillator (CRT-D)
Trial: 18759963
Drug: Combined anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined anticoagulation with unfractioned heparin (UFH) and tirofiban
Trial: 12149235
Drug: G‐CSF‐mobilized peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF‐mobilized peripheral blood hematopoietic stem cell transplantation (PBHSCT)
Trial: 9952152
Drug: Midazolam (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (100 microg/kg) administered as a rapid intravenous bolus dose every 4-6 hours
Trial: 7593731
Drug: Moclobemide 300
RxNorm normalized name: moclobemide 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 300 to 450 mg daily
Trial: 29297950
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg vaginal progesterone
Trial: 28707771
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg vaginal progesterone
Trial: 30452422
Drug: Edasalonexent (33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edasalonexent (33 mg/kg/day)
Trial: 30452422
Drug: Edasalonexent (67
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edasalonexent (67 mg/kg/day)
Trial: 30452422
Drug: Edasalonexent (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edasalonexent (all doses)
Trial: 30452422
Drug: Edasalonexent (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edasalonexent (after 7 days of dosing)
Trial: 18043999
Drug: Cilnidipine 10
RxNorm normalized name: Cilnidipine 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilnidipine 10 mg
Trial: 21539882
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of PCV
Trial: 21539882
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of PCV
Trial: 21539882
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of PCV
Trial: 21539882
Drug: 0 doses
RxNorm normalized name: mometasone furoate 220 mcg/actuation (30 doses) INHALATION AEROSOL POWDER, BREATH ACTIVATED (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 doses of PCV
Trial: 19388864
Drug: D&G combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D&G combination (3 g)
Trial: 19388864
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 capsules)
Trial: 19388864
Drug: Open-label D&G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label D&G (1.5 g/day for 6 months)
Trial: 2898268
Drug: BRL 26830A,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRL 26830A, 200 mg daily for two weeks then 400 mg daily for 18 weeks
Trial: 30347431
Drug: Verubecestat (MK-8931)
RxNorm normalized name: vitamin MK 7
DrugBank: Verubecestat (DB12285)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verubecestat (MK-8931) 20 mg
Trial: 30347431
Drug: Verubecestat (MK-8931)
RxNorm normalized name: vitamin MK 7
DrugBank: Verubecestat (DB12285)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verubecestat (MK-8931) 100 mg
Trial: 30347431
Drug: Verubecestat (MK-8931)
RxNorm normalized name: vitamin MK 7
DrugBank: Verubecestat (DB12285)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verubecestat (MK-8931) 450 mg
Trial: 30347431
Drug: Verubecestat (MK-8931)
RxNorm normalized name: vitamin MK 7
DrugBank: Verubecestat (DB12285)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verubecestat (MK-8931) 80 mg once daily for 14 days
Trial: 30347431
Drug: Verubecestat (MK-8931)
RxNorm normalized name: vitamin MK 7
DrugBank: Verubecestat (DB12285)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verubecestat (MK-8931) 150 mg once daily for 14 days
Trial: 28399935
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with VR training
Trial: 25794299
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methylphenidate (up to 5mg×3) for 4 weeks
Trial: 25794299
Drug: Normal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dose methylphenidate (up to 20mg×3) for 4 weeks
Trial: 25794299
Drug: Methylphenidate (60mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (60mg/day spread over three doses)
Trial: 25794299
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no medication for 4 weeks)
Trial: 23211647
Drug: FVFP supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FVFP supplement (fruit plus vegetable concentrate, fish oil and probiotics)
Trial: 23211647
Drug: FVFP supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FVFP supplement
Trial: 21477682
Drug: Mifepristone+misoprostol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone+misoprostol (200 mg mifepristone and 800 mcg buccal misoprostol 24 h later)
Trial: 21477682
Drug: Misoprostol-only (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol-only (800 mcg buccal misoprostol 24 h apart)
Trial: 16421418
Drug: Standard-Dose Anthracycline-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-Dose Anthracycline-Based Chemotherapy (SD-CT)
Trial: 3072307
Drug: Multivitamin preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin preparation for 12 days
Trial: 28626756
Drug: MyrLiq 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MyrLiq 400 mg/day
Trial: 28626756
Drug: MyrLiq 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MyrLiq 200 mg/day
Trial: 24330826
Drug: Agomelatine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine (25 mg/day p.o.) with immediate substitution
Trial: 24330826
Drug: Agomelatine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine (25 mg/day p.o.) with short-tapering of previous drug
Trial: 24330826
Drug: Agomelatine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine (25 mg/day p.o.) with long-tapering of previous drug
Trial: 18441708
Drug: monopril +
RxNorm normalized name: fosinopril sodium Oral Tablet [Monopril]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monopril + propranolol + heparin
Trial: 18441708
Drug: propranolol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol + heparin
Trial: 12612990
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral nutritional supplement 2 hours before lunch
Trial: 12612990
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral nutritional supplement 30 minutes before lunch
Trial: 7899060
Drug: Enhanced MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced MRI (superparamagnetic iron oxide); pulse sequences: SE 500/20 (T1WI), SE 2000/20 (PDWI), SE 2000/70 (T2WI); contrast medium dose: 10 mumoles Fe/kg, administered intravenously for more than 30 minutes.
Trial: 2559272
Drug: DTC 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTC 200 mg/m2 intravenously weekly for 16 weeks
Trial: 30783794
Drug: Chlorpromazine 25
RxNorm normalized name: chlorpromazine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine 25 mg
Trial: 28251894
Drug: Dermocosmetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermocosmetic treatment (containing lipohydroxyacid, nicotinamide, and piroctone-olamine)
Trial: 21099447
Drug: Maternal ω‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal ω‐3 fatty acid supplementation (1.6 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid)